Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25983199 | 0.91 | TSHR (0.50) | KMT2AALDH1A1LMNAMEN1CYP3A4 | |
| SCHEMBL2772366 | 0.87 | TSHR (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL2773433 | 0.87 | TSHR (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL7060888 | 0.87 | TSHR (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL7064464 | 0.87 | TSHR (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL2772125 | 0.87 | TSHR (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL5785042 | 0.85 | CACNA1A (0.57) | KMT2AALDH1A1MEN1TSHRSLC6A3 | |
| SCHEMBL2770397 | 0.83 | OPRM1 (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL6236413 | 0.83 | OPRM1 (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 | |
| SCHEMBL6234263 | 0.83 | OPRM1 (0.44) | KMT2AALDH1A1LMNAMEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111747950-B | Pyrimidine derivatives for the treatment of cancer | 深圳福沃药业有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-1057894-B1 | Esterase genes and uses of the same | SUMITOMO CHEMICAL CO (JP) | 2010-04-28 | — | — | EP | disclosed |
| EP-1316610-B1 | Preparation comprising an enzyme for asymmetrical hydrolysis of N-substituted C3-C4 cyclic imino-2-carboxylic acid ester and method of using the same | SUMITOMO CHEMICAL CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1308519-B1 | Process for improving optical purity of azetidine-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6936445-B2 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1201653-B1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL CO (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-6828129-B2 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-12-07 | — | — | US | disclosed |
| US-6812008-B2 | NUCLEOTIDE SEQUENCES CODING POLYPEPTIDE FOR USE IN THE GENERATION OF S-N-BENZYLAZETIDINE-2-CARBOXYLIC ACID | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-02 | — | — | US | disclosed |
| EP-0957089-B1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL CO (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-20030124683-A1 | Enzyme preparation and method of using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-03 | — | — | US | disclosed |
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-11-07 | — | — | US | disclosed |
| US-6410279-B1 | GENERATING PREFERENTIAL COMPOUND IN SOLUTION; OBTAIN N-SUBSTITUTED AZETIDINE-2-CARBOXYLIC ACID ESTER, INCUBATE WITH PREFERENTIAL ENZYME, RECOVER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1201653-A1 | Method for racemization of optically active azetidine-2-Carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | EP | disclosed |
| US-6166224-A | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6162621-A | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-12-19 | — | — | US | disclosed |
| EP-1057894-A2 | Esterase genes and uses of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0957089-A1 | Method for racemization of optically active azetidine-2-carboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-17 | — | — | EP | disclosed |
| EP-0855446-A2 | Process for producing optically active azetidine-2-carboxylic acid derivative | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-07-29 | — | — | EP | disclosed |
| US-4200628-A | ANTIBIOTICS, BACTERICIDES | SHIONOGI & CO., LTD. (JP) | 1980-04-29 | — | — | US | disclosed |
| EP-0001643-A2 | Aminoglycoside derivatives, process for their manufacture, pharmaceutical compositions and carboxylic acids | SHIONOGI & CO., LTD. (JP) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164727-A1 | Nucleotide sequences coding polypeptide for use as tool in genetic engineering | IMPDH2, INHA, IMPDH1 | KMT2A 4052/4885ALDH1A1 2545/4885LMNA 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.